qz.com

qz.com
Share

qz.com

 •  September 24

What is Allergan afraid of? On Sept. 8, drug maker Allergan announced it would transfer its patent on a widely used eye drug, Restasis, to a Mohawk tribe—a piece of legal gymnastics designed to evade patent challenges through inter partes review (IPR). IPRs are a little discussed process created by Congress in 2011 to lessen red tape and resolve...

qz.com

 •  February 14

The global pharmaceutical industry has long leaned on blockbuster drugs for common ailments like high cholesterol, arthritis and erectile dysfunction for the bulk of its profits. But the looming expiry of patents in the US on many of these drugs, along with slowing approval rates for new mass market drugs in development, is forcing a shift into...

qz.com

 •  February 14

This item has been corrected. It is not uncommon for single drugs to account for a large share of a drug company’s business. Of the world’s 11 largest pharmaceutical companies in 2012, six had single drugs bring in more than 10% of total sales. Bayer was the only drug maker without a single treatment grossing more than 5% of total sales. Bayer’s...

qz.com

 •  February 14

More than half of the world’s raw materials for opiate painkillers like morphine and codeine come from the remote island of Tasmania, but according to Big Pharma, it’s not enough. GlaxoSmithKline, Johnson & Johnson, and TPI Enterprises of Australia are lobbying the Australian government (paywall) to allow opium poppies to be grown on the mainland...